Clinical Trials | November 03, 2022
SRL Diagnostics inaugurates an upgraded laboratory at Gurugram
The laboratory is equipped to perform high-volume diagnostic testing services
The laboratory is equipped to perform high-volume diagnostic testing services
KDAH Indore is a super-speciality, patient-centric, tertiary-care institution located in the Nipaniya area of Indore.
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
Subscribe To Our Newsletter & Stay Updated
